5 results about "Carvedilol" patented technology

This invention discloses a novel use of carvedilol or its salts and compositions, as well as the composition and its preparation method. The β-blocker or pharmaceutical composition provided by this invention has good efficacy in preventing, treating, and / or alleviating drug-induced liver injury, effectively reducing mortality caused by this disease; simultaneously, it can significantly reduce serum transaminase levels, alleviate symptoms such as liver and spleen edema, and has a good inhibitory effect on pro-inflammatory cytokines. Furthermore, experimental results further indicate that the combination of the β-blocker and pharmaceutically acceptable excipients (steviosides and / or glycyrrhizate) has good safety and is easily dissolved, released, and / or absorbed, improving the bioavailability of carvedilol and exhibiting a synergistic effect, showing promising application prospects.

The present disclosure provides compositions that provide positive allosteric modulator compounds of the beta-adrenergic receptor in combination with a beta-arrestin-biased beta-blocker, such as carvedilol, for the treatment of cardiovascular diseases and disorders, such as hypertension and heart failure, wherein the effectiveness of the beta-blocker is enhanced by positively augmenting carvedilol-stimulated cellular responses.

The invention relates to the technical field of medicines, and relates to application of carvedilol in preparation of a novel coronavirus respiratory mucosa vaccine. The novel coronavirus respiratory mucosa vaccine is a vaccine which takes carvedilol as a unique immunologic adjuvant or a composite adjuvant containing capsaicin and is inoculated through a nasal drop or nasal spray way to prevent novel coronavirus infection. The recombinant new coronavirus spike protein is used as an antigen and is mixed with carvedilol, and the mixture is inoculated to a narla golden hamster in a nasal drop manner. Experimental results show that carvedilol can effectively promote a body to generate a specific antibody aiming at spike protein, so that the IgG level in serum is remarkably improved, and IgA response in alveolar lavage fluid is also enhanced. Therefore, a basis is provided for development of carvedilol as a respiratory mucosa vaccine adjuvant.

The invention provides a method for simultaneously determining silibinin and carvedilol in plasma by a positive and negative ion switching technology. The specific operation of the method comprises the following steps: adding an internal standard solution and an organic solvent into a plasma sample, and ensuring full extraction of silibinin and carvedilol through vortex mixing. Separating by utilizing a centrifugal technology, collecting supernate, diluting and taking the supernate as a pretreated to-be-detected sample; the method comprises the following steps: carrying out gradient elution by adopting a Scepter Phenyl-120 chromatographic column to realize effective separation of silibinin and carvedilol, and then carrying out mass spectrometric detection on a sample. A standard curve is drawn based on the mass spectrum peak area ratio, a regression equation is obtained, and the concentration of silibinin and carvedilol in the to-be-detected sample is obtained through calculation. The method has the characteristics of simplicity and convenience in pretreatment operation, low plasma consumption, short analysis time and high sensitivity, and is suitable for detection of silibinin and carvedilol in plasma and pharmacokinetic research of silibinin and carvedilol.

The present invention provides compositions comprising a monoamine oxidase inhibitor (MAOI) and a beta receptor blocker (e.g., a beta receptor inhibitor). The invention relates to a dosage form of two of propranolol, metoprolol, carvedilol, timolol, carteolol, atenolol, nebivolol, sotalol, bunenolol, naldalol, seribolol, nebivolol, betalol, esmolol, bisoprolol, oxyprenolol, pentobutolol, labeolol, acebutolol and indolol. And methods of making the dosage forms and using the dosage forms for, for example, the treatment of psychiatric disorders (e.g., depression, major depressive disorder, major depressive disorder associated with anxiety pain, refractory depression, anxiety depression, and mixed anxiety and depression). This abstract is intended as a scanning tool for search purposes in the particular art and is not intended as a limitation on the present invention.